Brokers Issue Forecasts for JSPR Q1 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Jasper Therapeutics in a research note issued to investors on Wednesday, January 8th. HC Wainwright analyst E. Bodnar expects that the company will earn ($1.48) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2025 earnings at ($1.63) EPS, Q3 2025 earnings at ($1.78) EPS, Q4 2025 earnings at ($1.93) EPS, FY2025 earnings at ($6.83) EPS, FY2026 earnings at ($8.17) EPS, FY2027 earnings at ($9.50) EPS and FY2028 earnings at ($10.61) EPS.

A number of other equities analysts also recently commented on the stock. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, Royal Bank of Canada cut their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $67.75.

Jasper Therapeutics Price Performance

JSPR stock opened at $6.69 on Monday. The company has a market cap of $100.36 million, a price-to-earnings ratio of -1.41 and a beta of 2.18. Jasper Therapeutics has a 12 month low of $6.30 and a 12 month high of $31.01. The company has a fifty day moving average price of $21.09 and a 200 day moving average price of $20.15.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its holdings in Jasper Therapeutics by 208.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC purchased a new stake in shares of Jasper Therapeutics during the third quarter worth about $59,000. MetLife Investment Management LLC grew its holdings in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock worth $129,000 after buying an additional 3,873 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Jasper Therapeutics during the third quarter worth about $251,000. Finally, Rhumbline Advisers purchased a new stake in shares of Jasper Therapeutics during the second quarter worth about $300,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.